Cutaneous vasculitis after COVID-19 vaccination in a 41-year-old male.
COVID‐19 infection
SARS‐CoV‐2 vaccine
cutaneous vasculitis
leukocytoclastic vasculitis
Journal
Clinical case reports
ISSN: 2050-0904
Titre abrégé: Clin Case Rep
Pays: England
ID NLM: 101620385
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
received:
03
03
2023
revised:
23
03
2023
accepted:
07
04
2023
medline:
8
5
2023
pubmed:
8
5
2023
entrez:
8
5
2023
Statut:
epublish
Résumé
Leukocytoclastic vasculitis could be a possible adverse event of different SARS-CoV-2 vaccines. Clinicians and manufacturers should be aware of this adverse event for appropriate diagnosis and treatment.
Identifiants
pubmed: 37155418
doi: 10.1002/ccr3.7238
pii: CCR37238
pmc: PMC10122690
doi:
Types de publication
Case Reports
Langues
eng
Pagination
e7238Informations de copyright
© 2023 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Dermatol Ther. 2022 Jun;35(6):e15458
pubmed: 35306713
Front Med (Lausanne). 2022 Aug 23;9:996288
pubmed: 36082274
Vaccine. 2016 Dec 12;34(51):6641-6651
pubmed: 26398442
J Autoimmun. 2022 Feb;127:102783
pubmed: 34973526
Clin Rev Allergy Immunol. 2021 Oct;61(2):181-193
pubmed: 32378145